EAS consensus statement on key biological mechanisms of LDL-c leading to ASCVDNews - Feb. 27, 2020
The European Atherosclerosis Society Consensus Panel has published a consensus statement on key biological mechanisms of LDL-c in the pathophysiology of atherosclerotic CVD (ASCVD). Established and newly emerging evidence on the biology of ASCVD at the molecular, cellular and tissue levels are discussed in this publication to answer the question which key biological mechanisms underlie the central role of LDL in the pathophysiology of ASCVD. The task of this Consensus Panel was to identify and highlight missing parts in the pathophysiology of ASCVD as target areas for future research, and potentially for development of new therapies to decrease the burden of ASCVD.
This second statement follows the first Consensus Statement with extensive evidence that LDL-c is causal in atherosclerosis.
This second statement includes consideration of factors that modulate the atherogenicity of LDL at the arterial wall and downstream effects by LDL particles on the atherogenic process. Evidence for the causal role of other apoB-containing lipoproteins in ASCVD is briefly mentioned. Pathophysiological and genetic components of ASCVD that are not fully understood are also described.